Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial

At 52 weeks, mepolizumab, in addition to standard of care, improved nasal polyp size (improved endoscopic nasal polyp score from baseline) and nasal obstruction (improved score from baseline at weeks 49–52) vs placebo (n=414; both p<0.0001) with no safety concerns.

Source:

The Lancet Respiratory Medicine